Glycaemic Control: A Balancing Act or A Different Approach?

Current Diabetes Reviews

Volumn 10, Issue 2, 2014, Pages 124-130

  Fava, Stephen ^a  

^a MATER DEI HOSPITAL   (Malta)

Author keywords

Diabetes mellitus; Glycaemic control; Hypoglycaemia; Treatment; Type 2 diabetes

Indexed keywords

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COGNITIVE DEFECT; DEMENTIA; DIABETES MELLITUS; FALLING; GERIATRIC PATIENT; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MEMORY DISORDER; MICROANGIOPATHY; MOOD DISORDER; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; MEMORY DISORDERS; METABOLISM; MILD COGNITIVE IMPAIRMENT; PREVALENCE; PREVENTION AND CONTROL;

ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ACCIDENTAL FALLS; ACUTE CORONARY SYNDROME; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MEMORY DISORDERS; MILD COGNITIVE IMPAIRMENT; PREVALENCE;

EID: 84925229161     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/1573399810666140421124051     Document Type: Article

References (78)

1. McDonald M, Hertz RP, Unger AN, Lustik MB. Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. J Gerontol A Biol http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2655011/ Sci Med Sci 2009; 64A: 256-63.
2. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
3. Sommerfield AJ, Deary IJ, Frier BM. Acute hyperglycaemia alters mood state and impairs cognitive performance in people with type 2 diabetes. Diabetes Care 2004; 27: 2335-40.
4. Davis EA, Soong SA, Byrne GC, Jones TW. Acute hyperglycaemia impairs cognitive function in children with IDDM. J Pediatr Endocrinol Metab 1996; 9: 455-61.
5. Cukierman-Yaffe T, Gerstein HC, Williamson JD, Lazar RM, Lovato L, Miller ME, Coker LH, Murray A, Sullivan MD, Marcovina SM, Launer LJ; Action to Control Cardiovascular Risk in Diabetes-Memory in Diabetes (ACCORD-MIND) Investigators. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetesmemory in diabetes (ACCORD-MIND) trial. Diabetes Care 2009; 32: 221-26.
6. Yaffe K, Falvey C, Hamilton N, Schwartz AV, Simonsick EM, Satterfield S, Cauley JA, Rosano C, Launer LJ, Strotmeyer ES, Harris TB. Diabetes, Glucose Control, and 9-Year Cognitivedecline among older adults without Dementia. Arch Neurol 2012; 18: 1-6.
7. Umegaki H, Iimuro S, Shinozaki T, Araki A, Sakurai T, Iijima K, Ohashi Y, Ito H; Japanese Elderly Diabetes Intervention Trial Study Group. Risk factors associated with cognitive decline in the elderly with type 2 diabetes: pooled logistic analysis of a 6-year observation in the Japanese Elderly Diabetes Intervention Trial. Geriatr Gerontol Int 2012; 12 Suppl 1: 110-6.
8. Christman AL, Matsushita K, Gottesman RF, Mosley T, Alonso A, Coresh J, Hill-Briggs F, Sharrett AR, Selvin E. Glycatedhaemoglobin and cognitive decline: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 2011; 54: 1645-52.
9. Mortimer JA, Borenstein AR, Ding D, Decarli C, Zhao Q, Copenhaver C, Guo Q, Chu S, Galasko D, Salmon DP, Dai Q, Wu Y, Petersen R, Hong Z. High normal fasting blood glucose is associated with dementia in Chinese elderly. Alzheimers Dement 2010; 6: 440-7.
10. Cukierman-Yaffe T, Gerstein HC, Anderson C, Zhao F, Sleight P, Hilbrich L, Jackson SH, Yusuf S, Teo K. ONTARGET/TRANSCEND Investigators. Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme. Diabetes Res Clin Pract 2009; 83: 387-93.
11. Rizzo MR, Marfella R, Barbieri M, Boccardi V, Vestini F, Lettieri B, Canonico S, Paolisso G. Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients. Diabetes Care 2010; 33, 2169-74.
12. Abbatecola AM, Rizzo MR, Barbieri M, Grella R, Arciello A, Laieta MT, Acampora R, Passariello N, Cacciapuoti F, Paolisso G. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006; 67: 235-40.
13. Zhong Y, Zhang XY, Miao Y, Zhu JH, Yan H, Wang BY, Jin J, Hu TJ, Jia WP. The relationship between glucose excursion and cognitive function in aged type 2 diabetes patients. Biomed Environ Sci 2012; 25; 1-7.
14. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26(3): 881-5.
15. Nilsson A, Radeborg K, Björck I. Effects on cognitive performance of modulating the postprandial blood glucose profile at breakfast. Eur J Clin Nutr 2012; 66(9): 1039-43.
16. Resnick HE, Harris MI, Brock DB, Harris TB. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care 2000; 23; 176-80.
17. Cardoso S, Correia S, Santos RX, Carvalho C, Candeias E, Duarte AI, Plácido AI, Santos MS, Moreira PI. Hyperglycaemia, hypoglycaemia and dementia: role of mitochondria and uncoupling proteins. Curr Mol Med 2013; 13(4): 586-601.
18. Huang X, Wang F, Chen W, Chen Y, Wang N, von Maltzan K. Possible link between the cognitive dysfunction associated with diabetes mellitus and the neurotoxicity of methylglyoxal proteins. Brain Res 2012; 1469; 82-91.
19. Car H, Zendzian-Piotrowska M, Prokopiuk S, Fiedorowicz A, Sadowska A, Kurek K, Sawicka. Ceramide profiles in the brain of rats with diabetes induced by streptozotocin. FEBS J 2012; 279: 1943-52.
20. Malone JI, Hanna S, Saporta S, Mervis RF, Park CR, Chong L, Diamond DM. Hyperglycaemia not hypoglycaemia alters neuronal dendrites and impairs spatial memory. Pediatr Diabetes 2008; 9: 531-39.
21. Strachan MW, Reynolds RM, Marioni RE, Price JF, Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol 2011; 7: 108-14.
22. Nguyen HT, Arcury TA, Grzywacz JG, Saldana SJ, Ip EH, Kirk JK, Bell RA, Quandt SA. The association of mental conditions with blood glucose levels in older adults with diabetes. Aging Ment Health 2012; 16(8): 950-7.
23. Fava S: Role of postprandial hyperglycaemia in cardiovascular disease. Exp Rev Cardiovasc Ther 2008; 6: 859-72.
24. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J. Risk factors for myocardial infarctionand death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-83.
25. Shaw JE Hodge AM, de Courten M, Chitson P, Zimmet PZ. Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 1999; 42; 1050-4.
26. The DECODE Study Group, European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of Diagnostic Criteria in Europe. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia 1999; 42: 647-54.
27. de Vegt F, Dekker JM, Ruhé HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the HoornStudy. Diabetologia 1999; 42; 926-31.
28. Ceriello, A. Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycaemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 2002; 106; 1211-8.
29. Watanabe K, Oba K, Suzuki T, Ouchi M, Suzuki K, Futami-Suda S, Sekimizu K, Yamamoto N, Nakano H. Oral glucose loading attenuates endothelial function in normal individual. Eur J Clin Invest 2001; 41: 465-73.
30. Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006; 91: 837-42.
31. Colette C, Monnier L. Acute glucose fluctuations and chronic sustained hyperglycaemiaas risk factors for cardiovascular diseases in patients with type 2 diabetes. Horm Metab Res 2007; 39: 683-6.
32. de Castro SH, Castro-Faria-Neto HC, Gomes MB. Association of postprandial hyperglycaemiawith in vitro LDL oxidation in nonsmoking patients with type 1 diabetes--a cross-sectional study. Rev Diabet Stud 2005; 2: 157-64.
33. Scognamiglio R, Negut C, De Kreutzenberg SV, Tiengo A, Avogaro A. Negut C, De Kreutzenberg SV, Tiengo A, Avogaro A. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation 2005; 112: 179-84.
34. Cai L, Li W, Wang G, Jiang Y, Kang YJ. Hyperglycaemia-induced apoptosis in the mouse myocardium. Diabetes 2002; 51: 1938-48.
35. Levy AR, Christensen TL, Johnson JA. Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health Qual Life Outcomes 2008; 6: 73.
36. Hitchen L. Doctors are failing to tell diabetic people about UK driving rules. BMJ 2006; 332(7545): 812.
37. Christensen TL, Johnson JA. Schwartz AV. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care. 2002; 25: 1749-54.
38. Schwartz AV, Vittinghoff E, Sellmeyer DE, Feingold KR, de Rekeneire N, Strotmeyer ES, Shorr RI, Vinik AI, Odden MC, Park SW, Faulkner KA, Harris TB. Health, Aging, and Body Composition Study. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care 2008; 31: 391-6.
39. Gonder-Frederick LA, Zrebiec JF, Bauchowitz AU, Ritterband LM, Magee JC, Cox DJ, Clarke WL. Cognitive function is disrupted by both hypo- and hyperglycaemia in school-aged children with type 1 diabetes: a field study. Diabetes Care 2009; 32: 1001-6.
40. Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycaemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 2009; 32: 1513-7.
41. Whitmer Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic Episodes and Risk of Dementia in Older Patients With Type 2 Diabetes Mellitus JAMA 2009; 301: 1565-72.
42. Caruana Galizia A, Fava S, Foale R. Nesidioblastosis-associated hypoglycaemia presenting with prominent cardiac manifestations. Postgrad Med J 1996; 72(846): 231-32.
43. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycaemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003; 26: 1485-9.
44. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, Dudl RJ, Ismail-Beigi F, Kimel AR, Hoogwerf B, Horowitz KR, Savage PJ, Seaquist ER, Simmons DL, Sivitz WI, Speril-Hillen JM, Sweeney ME. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study BMJ. 2010; 340: b4909.
45. Fava S Aquilina O, Azzopardi J, Agius Muscat H, Fenech FF. The prognostic value of blood glucose in diabetic Patients with acute myocardial infarction. Diabetic Med 1996; 13: 80-3.
46. Svensson AM, McGuire DK, Abrahamsson P, Dellborg M. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J 2005; 26: 1255-61.
47. Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ. Hypoglycaemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med J 2012; 124: 124-32.
48. Wright AD, Cull CA, Macleod KM, Holman RR; for the UKPDS Group. Hypoglycaemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73. J Diabetes Complicati 2006; 20: 395-401.
49. Type 2 diabetes. The Management of type 2 diabetes. National Institute for Health and Clinical Excellence, 2009. http: //www.nice.org.uk/nicemedia/live/12165/44320/44320.pdf. Accessed 7th January 2014.
50. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, Brancati FL. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386-99.
51. Matthews DR, Dejager S, Ahren B, Fonseca V, Ferrannini E, Couturier A, Foley JE, Zinman B. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2- year study. Diabetes Obes Metab 2010; 12: 780-7.
52. Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, Musser BJ, Davies MJ, Kaufman KD, Goldstein BJ. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord 2010; 22: 10: 7.
53. Irons BK, Weis JM, Stapleton MR, Edwards KL. An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors. Curr Diabetes Rev 2012; 8(3): 169-82.
54. Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic reviewof the benefits and risks of dipeptidyl peptidase-4 inhibitors. Am J Geriatr Pharmacother 2012; 8: 405-18.
55. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycaemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35: 1364-79.
56. Erhardt W, Bergenheim K, Duprat-Lomon I, McEwan P. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis. Clin Drug Investig 2012; 32: 189-202.
57. Grzeszczak W, Czupryniak L, Kolasa K, Sciborski C, Lomon ID, McEwan P. The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland. Diabetes Technol Ther 2012; 14: 65-73.
58. Valentine WJ, Bottomley JM, Palmer AJ, Brändle M, Foos V, Williams R, Dormandy JA, Yates J, Tan MH, Massi-Benedetti M; PROactive Study Group. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. Diabet Med 2007; 24: 982-1002.
59. Management of Diabetes/ The Scottish Intercollegiate Guideline Network. http://sign.ac.uk/pdf/qrg116.pdf. Accessed 7th January 2014.
60. Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, Elasy TA, Griffin MR. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 2012; 157(9): 601-10.
61. Johnson JA, Simpson SH, Toth EL, Majumdar SR. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabet Med 2005; 22, 497-502.
62. The University Group Diabetes Program: A study of the effect of hypoglycemic agents on vascular complication sin patients with adult-onset diabetes. Diabetes 1970; 19(Suppl 2); 747-830.
63. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
64. Krentz AJ, Bailey CJ.Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65: 385-411.
65. Lee P, Chang A, Blaum C, Vlajnic A, Gao L, Halter J. Comparison of safety and efficacy of insulin glargine and neutral protamine hagedorn insulin in older adults with type 2 diabetes mellitus: results from a pooled analysis. J Am Geriatr Soc 2012; 60: 51-9.
66. Marouf E, Sinclair AJ. Use of short-acting insulin aspart in managing older people with diabetes. Clin Interv Aging 2009; 4: 187-190.
67. Pollock RF, Erny-Albrecht KM, Kalsekar A, Bruhn D, Valentine WJ. Long-acting insulin analogs: a review of "real-world" effectiveness in patients with type 2 diabetes. Curr Diabetes Rev 2011; 7(1): 61-74.
68. Bhartia M, Tahrani AA, Barnett AH. SGLT-2 inhibitors in development for type 2 diabetes treatment. Rev Diabet Stud 2011 Fall; 8(3): 348-54.
69. Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium glucose cotransporter 2 (SGLT2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011; 32(4): 515-31.
70. Desouza CV. An overview of salsalate as a potential antidiabetic therapy. Drugs Today (Barc) 2010; 46(11): 847-53.
71. Koska J, Ortega E, Bunt JC, Gasser A, Impson J, Hanson RL, Forbes J, de Courten B, Krakoff J. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. Diabetologia 2009; 52(3): 385-93.
72. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE; TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team). The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2010; 152(6): 346-57.
73. Younk LM, Mikeladze M, Davis SN. Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin- Pharmacother 2011; 12(9): 1439-51.
74. Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2011; 13(2): 169-80.
75. Banerjee M, Saxena M. Interleukin-1 (IL-1) family of cytokines: role in type 2 diabetes. Clin Chim Acta 2012; 413(15-16): 1163-70.
76. Dinarello CA, Donath MY, Mandrup-Poulsen T. Role of IL-1beta in type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17(4): 314-21.
77. Akash MS, Shen Q, Rehman K, Chen S. Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus. J Pharm Sci 2012; 101(5): 1647-58.
78. Park K, Lee BM, Hyun KH, Lee DH, Choi HH, Kim H, Chong W, Kim KB, Nam SY. Discovery of 3-(4-methanesulfonylphenoxy)- N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin- 2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus. Bjoorg Med Chem 2014.